Immunotherapy Advances in Urothelial Carcinoma

被引：7

作者：

Jain, Rohit K. ^{[1
]}

Snyders, Travis ^{[2
]}

Nandgoapal, Lakshminarayanan ^{[3
]}

Garje, Rohan ^{[2
]}

Zakharia, Yousef ^{[2
]}

Gupta, Shilpa ^{[4
,5
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Univ Iowa, Iowa City, IA USA

[3] Univ Alabama Birmingham, Birmingham, AL USA

[4] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA

[5] Univ Minnesota, Dept Med, Hematol Oncol & Transplantat, 14-100 Phillips Wangensteen Bldg,MMC 480, Minneapolis, MN 55455 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2018年 / 19卷 / 12期

关键词：

Urothelial carcinoma; Immunotherapy; Biomarkers; Checkpoint inhibitors; CISPLATIN-INELIGIBLE PATIENTS; TUMOR MUTATIONAL BURDEN; INVASIVE BLADDER-CANCER; SINGLE-ARM; OPEN-LABEL; CHECKPOINT BLOCKADE; CELL-CARCINOMA; PHASE-II; MULTICENTER; THERAPY;

D O I：

10.1007/s11864-018-0598-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Opinion statementCheckpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Several immunotherapy trials are ongoing in non-metastatic setting to maximize responses upfront. Despite the promising responses with immunotherapy, majority of patients do not respond to monotherapy and combination approaches would be the path moving forward to maximize responses. In addition, novel therapies are needed for patients who progress on checkpoint inhibitors. There is still a lot to be done to better understand predictive biomarkers, optimal combination, and sequences to improve clinical outcomes in urothelial carcinoma.

引用

页数：14

共 41 条

[1] Biomarkers for immunotherapy in bladder cancer: a moving target [J].

Aggen, David H. ;

Drake, Charles G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[2] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[3]

[Anonymous], 2018, J CLIN ONCOL S

[4]

[Anonymous], J CLIN ONCOL S

[5] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[6] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[7] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[8] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[9] T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival [J].

Boorjian, Stephen A. ;

Sheinin, Yuri ;

Crispen, Paul L. ;

Farmer, Sara A. ;

Lohse, Christine M. ;

Kuntz, Susan M. ;

Leibovich, Bradley C. ;

Kwon, Eugene D. ;

Frank, Igor .

CLINICAL CANCER RESEARCH, 2008, 14 (15) :4800-4808

[10] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J].

Boussiotis, Vassiliki A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1767-1778

← 1 2 3 4 5 →